The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer

Clinical positron imaging : official journal of the Institute for Clinical P.E.T Pub Date : 2000-03-01 DOI:10.1016/S1095-0397(00)00042-X

Max Lonneux MD , Ivan Borbath MD , Martine Berlière MD , Carine Kirkove MD , Stanislas Pauwels MD, PhD

{"title":"The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer","authors":"Max Lonneux MD , Ivan Borbath MD , Martine Berlière MD , Carine Kirkove MD , Stanislas Pauwels MD, PhD","doi":"10.1016/S1095-0397(00)00042-X","DOIUrl":null,"url":null,"abstract":"<div>Purpose: To study the role of positron emission tomography 18F-fluorodeoxyglucose (PET FDG) imaging in patients with a suspicion of breast cancer recurrence.Procedures: Whole-body PET FDG was performed in 39 women. Thirty-four were included because of asymptomatic tumor marker increase. PET findings were confirmed by oriented imaging or by biopsy. Follow-up data were collected over a period of at least 12 months.Results: PET FDG depicted 37/39 sites in 31/33 patients with recurrence. PET missed one locoregional recurrence and in one patient peritoneal carcinomatosis developed 6 months after a negative PET. False positive PET FDG corresponded to lung infection, degenerative bone disease, and reconstruction artifact. The conventional imaging work-up depicted sites of recurrence in 6/33 patients.Conclusion: Whole-body PET FDG is highly sensitive for the detection of distant breast cancer recurrence. Prospective studies are mandatory to address its potential impact on patient management and survival.</div>","PeriodicalId":80267,"journal":{"name":"Clinical positron imaging : official journal of the Institute for Clinical P.E.T","volume":"3 2","pages":"Pages 45-49"},"PeriodicalIF":0.0000,"publicationDate":"2000-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1095-0397(00)00042-X","citationCount":"94","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical positron imaging : official journal of the Institute for Clinical P.E.T","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S109503970000042X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 94

Abstract

Purpose: To study the role of positron emission tomography ¹⁸F-fluorodeoxyglucose (PET FDG) imaging in patients with a suspicion of breast cancer recurrence.

Procedures: Whole-body PET FDG was performed in 39 women. Thirty-four were included because of asymptomatic tumor marker increase. PET findings were confirmed by oriented imaging or by biopsy. Follow-up data were collected over a period of at least 12 months.

Results: PET FDG depicted 37/39 sites in 31/33 patients with recurrence. PET missed one locoregional recurrence and in one patient peritoneal carcinomatosis developed 6 months after a negative PET. False positive PET FDG corresponded to lung infection, degenerative bone disease, and reconstruction artifact. The conventional imaging work-up depicted sites of recurrence in 6/33 patients.

Conclusion: Whole-body PET FDG is highly sensitive for the detection of distant breast cancer recurrence. Prospective studies are mandatory to address its potential impact on patient management and survival.

查看原文本刊更多论文

全身PET FDG在乳腺癌远处复发诊断中的地位

目的:探讨正电子发射断层扫描18f -氟脱氧葡萄糖(PET FDG)在怀疑乳腺癌复发患者中的作用。方法:对39名女性进行全身PET FDG检查。34例因无症状肿瘤标志物升高而被纳入。PET结果经定向成像或活检证实。随访数据收集时间至少为12个月。结果:31/33例复发患者PET FDG显示37/39个部位。PET未发现1例局部复发，1例患者在PET阴性6个月后出现腹膜癌。PET FDG假阳性对应肺部感染、退行性骨病和重建伪影。常规影像学检查描述了6/33例患者的复发部位。结论:全身PET FDG检测远处乳腺癌复发具有较高的敏感性。前瞻性研究是强制性的，以解决其对患者管理和生存的潜在影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical positron imaging : official journal of the Institute for Clinical P.E.T

自引率

0.00%

发文量